trial summary · NCT07350863
U69-CART-Cells For R/R T-ALL
A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of U69 in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma, sponsored by The First Affiliated Hospital of Soochow University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Overall Introduction This single-arm, open-label clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection (CXCR4 CCR9 CAR-T) in patients with relapsed or refractory T-lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL). Additionally, the study seeks to preliminarily assess the efficacy of CXCR4 CCR9 CAR-T cells and explore the appropriate dosage and administration schedule for subsequent Phase II clinical trials. A dose escalation study following the 3+3 design was implemented across three dose cohorts, with each cohort planned to enroll 3 to 6 patients, totaling 9 to 18 participants. Following cell infusion, subjects underwent safety and efficacy follow-up, which continued until 2 years post-infusion, subject withdrawal, or study termination-whichever occurred first. For subjects with available follow-up information after study completion or early termination, long-term follow-up-including long-term safety monitoring-was conducted for up to 15 years.
Source record: https://clinicaltrials.gov/study/NCT07350863
Facts
| registry id | NCT07350863 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma |
| sponsor | The First Affiliated Hospital of Soochow University |
| sponsor class | OTHER |
| enrollment | 12 |
| start date | 2026-10-25 |
| primary completion | 2026-12-15 |
| completion | 2028-07-15 |
| results posted | not reported |
Conditions
- Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Interventions
- CXCR4 CCR9 CAR-T
Countries
- China
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.